Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Depression
Interventions: Ketamine Hydrochloride, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Chronic Tympanic Membrane Perforation
Interventions: Fibroblast Growth Factor 2, Saline control; Drug
Lead sponsor: D. Bradley Welling, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endometriosis, Chronic Pelvic Pain, Pelvic Muscle Spasm, Quality of Life
Interventions: Botulinum toxin (BoNT), Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glioblastoma
Interventions: Zimberelimab, Domvanalimab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: San Francisco, California • New Haven, Connecticut • Boston, Massachusetts

Conditions: Chronic Sinusitis
Interventions: IV Acetaminophen, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 68 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Diabetic
Interventions: REMD-477 versus Placebo, Exogenous glucagon versus saline infusion; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Cocaine Dependence
Interventions: TA-CD Vaccination, Placebo Injection; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Asthma
Interventions: GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Orange, California • Torrance, California • Aurora, Colorado + 8 more

Conditions: Kidney Failure
Interventions: rhC1INH, Saline Solution; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: ASC-US, ASC-H, LSIL
Interventions: PVX-2, Placebo; Biological · Other
Lead sponsor: PapiVax Biotech, Inc.; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more

Conditions: Burns, Growth Hormone Treatment
Interventions: Somatropin, 0.09% Saline Solution; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Sedation
Interventions: Midazolam, xylocaine, saline placebo; Drug
Lead sponsor: Jennifer Victory, RN, CCRC; Other
Eligibility: 18 Months to 7 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Psoriasis
Interventions: CC-90006, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Anaheim, California • Fair Lawn, New Jersey • Duncansville, Pennsylvania

Conditions: Advanced Cancers, Dyspnea
Interventions: Fentanyl, Placebo, Walking Tests, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Use Disorder
Interventions: Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Influenza A
Interventions: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,977 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Inflammatory Response
Interventions: Ibuprofen, Placebo/Saline solution; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Critical Limb Ischemia
Interventions: Low Dose VM202, High Dose VM202, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more

Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions: Oregovomab, Paclitaxel, Carboplatin, Placebo; Biological · Drug
Lead sponsor: CanariaBio Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more

Conditions: Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
Interventions: Saline, Ketamine; Drug
Lead sponsor: Eric Johnson; Other
Eligibility: 18 Years to 90 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

A Study of Abatacept in Patients With Active Crohn's Disease

In-office Repair of Chronic Tympanic Membrane Perforations

Botulinum Toxin for Pelvic Pain in Women With Endometriosis

AB154 Combined With AB122 for Recurrent Glioblastoma

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

Multisite Controlled Trial of Cocaine Vaccine

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients

Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Breakthrough Dyspnea Fentanyl Study in Cancer Patients

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI